CN115151538B - 新的大环化合物、它们的制备方法和含有它们的药物组合物 - Google Patents

新的大环化合物、它们的制备方法和含有它们的药物组合物

Info

Publication number
CN115151538B
CN115151538B CN202180016377.4A CN202180016377A CN115151538B CN 115151538 B CN115151538 B CN 115151538B CN 202180016377 A CN202180016377 A CN 202180016377A CN 115151538 B CN115151538 B CN 115151538B
Authority
CN
China
Prior art keywords
methyl
dioxo
benzotriazol
title compound
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180016377.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN115151538A (zh
Inventor
C·韦伯
K·西多夫
D·杜兰德
M·久里斯
A·基斯
Z·马达雷斯
M·莫尔纳
M·尼尔格
M·鲁达索娃
A·萨皮
S·伯格
V·杜维维尔
V·马丁尼
I·特里特
C·文森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of CN115151538A publication Critical patent/CN115151538A/zh
Application granted granted Critical
Publication of CN115151538B publication Critical patent/CN115151538B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180016377.4A 2020-02-28 2021-02-26 新的大环化合物、它们的制备方法和含有它们的药物组合物 Active CN115151538B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20305207.1 2020-02-28
EP20305207 2020-02-28
PCT/EP2021/054780 WO2021170774A1 (en) 2020-02-28 2021-02-26 New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
CN115151538A CN115151538A (zh) 2022-10-04
CN115151538B true CN115151538B (zh) 2026-02-27

Family

ID=70977485

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180016377.4A Active CN115151538B (zh) 2020-02-28 2021-02-26 新的大环化合物、它们的制备方法和含有它们的药物组合物

Country Status (12)

Country Link
US (1) US20230097678A1 (https=)
EP (1) EP4110776A1 (https=)
JP (1) JP7757298B2 (https=)
KR (1) KR20220148851A (https=)
CN (1) CN115151538B (https=)
AR (1) AR121435A1 (https=)
AU (1) AU2021226994A1 (https=)
BR (1) BR112022016286A2 (https=)
IL (1) IL295595B1 (https=)
MX (1) MX2022010673A (https=)
TW (1) TWI891735B (https=)
WO (1) WO2021170774A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014680A (es) 2019-05-31 2022-04-06 Ube Corp Derivado de benzotriazol.
CN114028374A (zh) * 2021-12-01 2022-02-11 江苏省人民医院（南京医科大学第一附属医院） 富马酸二甲酯在制备用于保护胰岛β细胞功能的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829305A (zh) * 2013-12-18 2016-08-03 葛兰素史密斯克莱知识产权发展有限公司 Nrf2调节剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105829305A (zh) * 2013-12-18 2016-08-03 葛兰素史密斯克莱知识产权发展有限公司 Nrf2调节剂

Also Published As

Publication number Publication date
TWI891735B (zh) 2025-08-01
US20230097678A1 (en) 2023-03-30
IL295595A (en) 2022-10-01
AU2021226994A1 (en) 2022-09-08
BR112022016286A2 (pt) 2022-12-13
AR121435A1 (es) 2022-06-08
CA3170840A1 (en) 2021-09-02
KR20220148851A (ko) 2022-11-07
IL295595B1 (en) 2026-01-01
JP7757298B2 (ja) 2025-10-21
CN115151538A (zh) 2022-10-04
JP2023515572A (ja) 2023-04-13
TW202144367A (zh) 2021-12-01
EP4110776A1 (en) 2023-01-04
WO2021170774A1 (en) 2021-09-02
MX2022010673A (es) 2022-09-23

Similar Documents

Publication Publication Date Title
US12358875B2 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis
KR102692309B1 (ko) Fxr (nr1h4) 조정 화합물
JP2009269819A (ja) アミン化合物
CN115151538B (zh) 新的大环化合物、它们的制备方法和含有它们的药物组合物
KR20210106528A (ko) 3-메틸-1,2,4-티아디아졸-5-카보하이드라지드 또는 이의 메틸-d3 중수소화 형태의 합성
US20220119391A1 (en) Macrocyclic compound and use thereof
CZ213995A3 (en) Novel derivatives of 3-hydroxyanthranilic acid, processes and intermediates of their preparation, novel pharmaceutical preparations and their use
CA2696237A1 (fr) Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique
CN114539267A (zh) 一种吴茱萸碱衍生物及其应用
CA3170840C (en) Macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them
HK40078242A (en) New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them
EP2396320B1 (fr) Derives de 3-benzofuranyl-indol-2-one substitues en position 3, leur preparation et leur application en therapeutique
EP2396319B1 (fr) Derives de 3-benzofuranyl-indol-2-one-3-acetamidopiperazines substitues, leur preparation et leur application en therapeutique
EA050508B1 (ru) Новые макроциклические соединения, способ их получения и содержащие их фармацевтические композиции
EP4342530A1 (en) Sortilin modulators
EP0686145B1 (en) New compounds
US12378260B2 (en) Benzotriazole compound
US20230310376A1 (en) Prophylactic and/or therapeutic agent for idiopathic pulmonary fibrosis
WO2005095364A1 (ja) フェノキシ酢酸誘導体及びそれを用いた医薬
Abed Structure-activity relationships of small molecule direct inhibitors of Keap1-Nrf2 interaction
HK40109860B (en) Fxr (nr1h4) modulating compounds
CN116063298A (zh) Wnt通路抑制剂的代谢物
WO2021110138A1 (zh) 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用
HK40062458A (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
KKiec-Kononowicz et al. STRUCTURE AND ACTIVITY STÜHES OF GLYCINE RECEPTOR L1GANDS. PART 2. IMIDAZOQl INAZOLINODIONE-DERIVATIVES WITH THE EXPECTED ANTICONVULSANT ACTIVITY

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078242

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant